| Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing solutions for people suffering from acute cannabinoid intoxication (ACI) and addiction. Co.'s primary product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, to address the unmet medical need for an antidote for ACI. ANEB-001 is an orally bioavailable absorbed treatment that will reverse the symptoms of ACI. Co.'s proprietary position in the treatment of ACI is protected by rights to several patent applications covering various methods of use of the compound and delivery systems. The ANEB YTD return is shown above.
The YTD Return on the ANEB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ANEB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANEB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.